Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q92794
UPID:
KAT6A_HUMAN
Alternative names:
MOZ, YBF2/SAS3, SAS2 and TIP60 protein 3; Monocytic leukemia zinc finger protein; Runt-related transcription factor-binding protein 2; Zinc finger protein 220
Alternative UPACC:
Q92794; Q76L81
Background:
Histone acetyltransferase KAT6A, also known as MOZ, YBF2/SAS3, SAS2, and TIP60 protein 3, plays a pivotal role in chromatin remodeling and gene expression regulation. It acetylates lysine residues in histone H3 and H4, contributing to the transcriptional activation of genes. KAT6A is a component of the MOZ/MORF complex, enhancing its histone H3 acetyltransferase activity. It also serves as a transcriptional coactivator for RUNX1 and RUNX2 and modifies p53/TP53, influencing its transcriptional activity.
Therapeutic significance:
KAT6A's mutation is linked to Arboleda-Tham syndrome, characterized by intellectual disability and delayed development. Understanding KAT6A's role could unveil new therapeutic strategies for this genetic disorder.